Hamza Tanveer, Doctor Of Pharmacy, Intern At WHO, NIH, Pam shared a post on LinkedIn:
“What if lung cancer drugs could finally reach the brain?
HER2-mutant NSCLC: lung cancer driven by HER2 gene mutation.
Blood–Brain Barrier: the brain’s filter, blocking many drugs. This is the barrier in lung cancer that usually stops us in our tracks. For patients with HER2-mutant NSCLC, the cancer doesn’t just stay in the lungs. It often spreads to the brain. And for years, the brain felt like a ‘fortress.’ Protected by the Blood–Brain Barrier… keeping many of our best treatments out.
Then came new data from the Beamion LUNG-1 study presented at ELCC 2026.
And that wall? It’s starting to crack.
The spotlight is on a new drug: Zongertinib
A highly selective HER2 TKI, designed to hit cancer cells while sparing normal ones.
The story the data tells:
Strong responses:
77% of patients responded
- 8% complete response
- 69% partial response
Disease control:
96% had their disease controlled
Durability:
~80% of patients maintained response at 6 months
Brain activity:
Shows meaningful control of brain metastases (crosses the barrier)
Safety:
No grade 4/5 toxicities
Most side effects were mild (e.g., diarrhea, mild liver enzyme rise)
- We may finally have a targeted first-line option for HER2+ lung cancer
- Brain metastases might not always need immediate radiation. A pill could control both lung and brain disease.
So, - Better targeting = better quality of life
The future of oncology isn’t just about survival. It’s about survival with clarity, function, and dignity.”
Further Reading․
Title: LBA74 Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 1
Authors: S. Popat, N. Yamamoto, N. Girard, Y-L. Wu, G. Ruiter, E.F. Smit, K. Yoh, H. Tu, J. Zugazagoitia, J. Sabari, T.C. Wehler, E. Nadal, J. Stöhr, B. Sadrolhefazi, H. Luess, J. Heymach
Read the Full Article.
Title: Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
Authors: John V. Heymach, Gerrina Ruiter, Myung-Ju Ahn, Nicolas Girard, Egbert F. Smit, David Planchard, Yi-Long Wu, Byoung Chul Cho, Noboru Yamamoto, Joshua K. Sabari, Yanqiu Zhao, Hai-Yan Tu, Kiyotaka Yoh, Ernest Nadal, Behbood Sadrolhefazi, Maren Rohrbacher, Ute von Wangenheim, Sabina Eigenbrod-Giese, Jon Zugazagoitia
Read the Full Article.
Other articles about NSCLC On OncoDaily.